Literatur
- 1
Kannel W B.
Vital epidemiologic clues in heart failure.
J Clin Epidemiol.
2000;
53
229-235
- 2
MacIntyre K, Capewell S, Stewart S, Chalmers J W, Boyd J, Finlayson A, Redpath A,
Pell J P, McMurray J J.
Evidence of improving prognosis in heart failure: trends in case fatality in 66 547
patients hospitalized between 1986 and 1995.
Circulation.
2000;
102
1126-1131
- 3
Jiang W, Alexander J, Christopher E, Kuchibhatla M, Gaulden L H, Cuffe M S, Blazing M A.
et al .
Relationship of depression to increased risk of mortality and rehospitalization in
patients with congestive heart failure.
Arch Intern Med.
2001;
161
1849-1856
- 4
Boersma E, Keil U, de Bacquer D, de Backer G, Pyorala K, Poldermans D, Leprotti C.
et al .
Blood pressure is insufficiently controlled in European patients with established
coronary heart disease.
J Hypertens.
2003;
21
1831-1840
- 5
Archacki S, Wang Q.
Expression profiling of cardiovascular disease.
Hum Genomics.
2004;
1
355-370
- 6
Grzeskowiak R, Witt H, Drungowski M, Thermann R, Hennig S, Perrot A, Osterziel K J.
et al .
Expression profiling of human idiopathic dilated cardiomyopathy.
Cardiovasc Res.
2003;
59
400-411
- 7
Cascorbi I, Paul M, Kroemer H K.
Pharmacogenomics of heart failure - focus on drug disposition and action.
Cardiovasc Res.
2004;
64
32-39
- 8
Crackower M A, Sarao R, Oudit G Y, Yagil C, Kozieradzki I, Scanga S E, Oliveira-dos-Santos A J.
et al .
Angiotensin-converting enzyme 2 is an essential regulator of heart function.
Nature.
2002;
417
822-828
- 9
Small K M, Wagoner L E, Levin A M, Kardia S L, Liggett S B.
Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk
of congestive heart failure.
N Engl J Med.
2002;
347
1135-1142
- 10
Group M-H S.
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention
Trial in Congestive Heart Failure (MERIT-HF).
Lancet.
1999;
353
2001-2007
- 11
White H L, de Boer R A, Maqbool A, Greenwood D, van Veldhuisen D J, Cuthbert R, Ball S G,
Hall A S, Balmforth A J.
An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals
with heart failure: a MERIT-HF sub-study.
Eur J Heart Fail.
2003;
5
463-468
- 12
Schönberger J, Seidman C E.
Many roads lead to a broken heart: the genetics of dilated cardiomyopathy.
Am J Hum Genet.
2001;
69
249-260
- 13
Seidman J G, Seidman C.
The genetic basis for cardiomyopathy: from mutation identification to mechanistic
paradigms.
Cell.
2001;
104
557-567
- 14
Olson T M, Michels V V, Thibodeau S N, Tai Y S, Keating M T.
Actin mutations in dilated cardiomyopathy, a heritable form of heart failure.
Science.
1998;
280
750-752
- 15
Taylor M R, Fain P R, Sinagra G, Robinson M L, Robertson A D, Carniel E, di Lenarda A.
et al .
Natural history of dilated cardiomyopathy due to lamin A/C gene mutations.
J Am Coll Cardiol.
2003;
41
771-780
- 16
Tanigawa G, Jarcho A J, Kaas S, Solomon D S, Vosberg H-P, Seidman J G, Seidman C.
A Molecular Basis for Familial Hypertrophic Cardiomyopathie: An a/β Cardiac Myosin
Heavy Chain Hybrid Gene.
Cell.
1990;
62
991-998
- 17
Arad M, Seidman J G, Seidman C E.
Phenotypic diversity in hypertrophic cardiomyopathy.
Hum Mol Genet.
2002;
11
2499-2506
- 18
Thierfelder L, Watkins H, MacRae C, Lamas R, McKenna W, Vosberg H P, Seidmann J G,
Seidmann C E.
Tropomyosin and Cardiac Troponin T Mutations Cause Familial Hypertrophic Cardiomyopathy:
A Disease of the Sarcomere.
Cell.
1994;
77
701-712
- 19
Geier C, Perrot A, Ozcelik C, Binner P, Counsell D, Hoffmann K, Pilz B. et al .
Mutations in the human muscle LIM protein gene in families with hypertrophic cardiomyopathy.
Circulation.
2003;
107
1390-1395
- 20
Blair E, Redwood C, Ashrafian H, Oliveira M, Broxholme J, Kerr B, Salmon A, Ostman-Smith I,
Watkins H.
Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic
cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis.
Hum Mol Genet.
2001;
10
1215-1220
- 21
Jung M, Poepping I, Perrot A, Ellmer A E, Wienker T F, Dietz R, Reis A, Osterziel K J.
Investigation of a family with autosomal dominant dilated cardiomyopathy defines a
novel locus on chromosome 2q14-q22.
Am J Hum Genet.
1999;
65
1068-1077
- 22
Maron B J, Niimura H, Casey S A, Soper M K, Wright G B, Seidman J G, Seidman C E.
Development of left ventricular hypertrophy in adults in hypertrophic cardiomyopathy
caused by cardiac myosin-binding protein C gene mutations.
J Am Coll Cardiol.
2001;
38
315-321
- 23
Nimura H, Bachinski L L, Sangwatanaroj S, Watkins H, Cudley A E, McKenna W, Kristinsson A.
et al .
Mutations in the gene for cardiac myosin-binding protein C and late-onset familial
hypertrophic cardiomyopathy.
New England Journal of Medicine.
1998;
338
1248-1257
- 24
Fatkin D, MacRae C, Sasaki T, Wolff M R, Porcu M, Frenneaux M, Atherton J.
Missense Mutations in the Rod Domain of the Lamin A/C Gene as Causes of Dilated Cardiomyopathy
and Conduction-System Disease.
New England Journal of Medicine.
1999;
341
1715-1724
Prof. Dr. med. Karl Josef Osterziel
Charité - Universitätsmedizin Berlin, Campus Buch, Franz-Volhard- Klinik, Medizinische
Klinik mit Schwerpunkt Molekulare und Klinische Kardiologie
Wiltbergstraße 50 · 13125 Berlin
Email: osterziel@fvk-berlin.de